Combination therapy with nivolumab and bevacizumab appeared to have clinical activity in ovarian cancer patients with platinum-sensitive or platinum-resistant disease.
A new study looked at trametinib's effect on survival and response rates in ovarian cancer.
The results of the first therapy to use a PARP inhibitor with chemotherapy for patients with ovarian cancer were presented at ESMO Congress 2019.
Maintenance therapy with niraparib may improve survival in patients with ovarian cancer.
Adding PARP inhibitors to maintenance therapy was shown to prolong progression-free survival in patients with advanced ovarian cancer.
The AVANOVA2 trial enrolled a total of 97 patients with high-grade serous or endometrioid platinum-sensitive recurrent ovarian cancer.
More ovarian cancer patients were willing to accept riskier surgery in exchange for better chances of extending their overall survival, according to a new study.
How much do you know about the role of long non-coding RNAs in ovarian cancer? Now is your chance to find out.
ESR2 rs3020450 polymorphism was linked to ovarian cancer risk at a population level, while high ESR2 expression levels were associated with long survival in ovarian cancer patients.
Using two validation methods, researchers found that a simple biomarker panel may have strong predictive ability for detecting ovarian cancer.